OraSure Technologies, Inc.
Moat Score — OraSure Technologies, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | OraSure holds FDA premarket approval making OraQuick® the only over-the-counter, oral-fluid HIV self-test sold in the United States, and no other FDA-approved rapid HCV test exists domestically either. These approvals are genuine, hard-to-replicate regulatory IP, but they protect a narrow set of niches rather than a broad patent estate, and newly acquired assets like Sherlock Biosciences' molecular platform are still unproven. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | OraSure is not a low-cost producer: its own 10-K notes that rival HIV/HCV tests outside the U.S. and competing genomics collection devices are often priced at or below its products. Manufacturing is concentrated in a single Bethlehem, PA facility plus limited contract assembly in Thailand, which constrains scale economics rather than enabling them. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | The collapse of InteliSwab® COVID revenue from roughly $257 million (2023) to near zero (2025) as the category commoditized shows OraSure has little pricing power outside its narrow OraQuick® HIV niche. Internationally, competing rapid HIV/HCV tests are frequently priced at or below OraSure's oral-fluid products, limiting leverage even in its core franchise. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | OraSure's diagnostic tests and sample-collection devices are standalone products used by individual patients, clinics, or labs; there is no mechanism by which one additional user or data point makes the product more valuable to others. This is a genuine, easily-identified weakness in the business model. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | DNA Genotek's Oragene® and ORAcollect® saliva collection kits and OMNIgene® microbiome stabilization products are validated into customers' established academic and commercial research protocols, creating real but modest friction to switch mid-study. Public-health program incumbency (e.g., long-standing African HIV testing relationships) adds some stickiness, though overall switching costs are far short of mission-critical enterprise software. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | OraSure describes itself as one of only a few vendors offering a standardized commercial microbiome stabilization solution, and the U.S. OTC oral-fluid HIV test market is a small niche most large diagnostics players have not bothered to contest directly. That said, this reflects limited market size more than a strong scale moat, and InteliSwab's COVID-era scale advantage evaporated entirely once demand normalized. |